Milne, Sarah C. http://orcid.org/0000-0002-9406-8609
Kim, Seok Hun
Murphy, Anna
Larkindale, Jane
Farmer, Jennifer
Malapira, Ritchie
Danoudis, Mary
Shaw, Jessica
Ramakrishnan, Tyagi
Rasouli, Fatemeh
Yiu, Eppie M.
Georgiou-Karistianis, Nellie
Tai, Geneieve
Zesiewicz, Theresa
Delatycki, Martin B.
Corben, Louise A.
Funding for this research was provided by:
Friedreich's Ataxia Research Alliance
National Health and Medical Research Council (APP1093259, APP 1073323, APP1143098)
Article History
Accepted: 17 November 2021
First Online: 2 December 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Monash Health Human Research Ethics Committee (15035A) and the USF Institutional Review Board (Pro00021414).
: All participants (or their parents/guardians if aged under 18 years) provided informed consent as per the Declaration of Helsinki.
: This study was sponsored by the Friedreich’s Ataxia Research Alliance (USA) (FARA), PTC Therapeutics and Voyager Therapeutics, as a part of FARA’s Biomarker Consortium. S. C. Milne received a National Health and Medical Research Council of Australia Postgraduate Scholarship (APP1093259). E. M. Yiu is a National Health and Medical Research Council Early Career Fellow (APP 1073323). L. A. Corben is a Medical Research Futures Fund Career Development Fellow (APP1143098). J. Larkindale was employed by the Friedreich’s Ataxia Research Alliance. J. Farmer is employed by the Friedreich’s Ataxia Research Alliance. S. H. Kim, A. Murphy, R. Malapira, M. Danoudis, J. Shaw, T. Ramakrishnan, F. Rasouli, N. Georgiou-Karistianis, G. Tai, T. Zesiewicz and M.B. Delatycki declare they have no financial or non-financial interests to disclose.